Loading
A phase 2 trial of Afamitresgene autoleucel in sarcomas, run by USWM CT, LLC, active and no longer recruiting.
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma is a phase 2 interventional study registered as NCT04044768 by USWM CT, LLC, with 52 participants enrolled, started 2019-08-13 and due to reach its primary completion in 2021-08-29. Interventions recorded: afamitresgene autoleucel (previously ADP-A2M4). Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
52 enrolled.
95% CI 24.36 to 54.50; Figures from the ClinicalTrials.gov results section (first posted 2025-01-13), not from a publication · 95% CI 3.19 to 65.09
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) (Cohort 1)primary | Synovial Sarcoma | 44 | 38.6% | - | - | link |
| MRCLS | 8 | 25% |
Shares Liposarcoma, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Liposarcoma and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares TCR-T cell therapy and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.